RELAVE Emmanuelle

My PhD research project focuses on evaluating the therapeutic potential of novel thiazoloflavonoid derivatives targeting the Tau protein in glioblastoma (GBM). Glioblastoma is the most common and aggressive form of primary malignant brain tumors, characterized by limited therapeutic options and poor patient prognosis, emphasizing the urgent need for innovative treatments. The synthesis of these novel compounds is performed by our collaborator Dr. Maxime Robin (IMBE, Aix-Marseille University). My role involves evaluating their therapeutic efficacy in relevant cellular and ex vivo GBM models, both alone and in combination with temozolomide (TMZ)—the current standard chemotherapy. Furthermore, I investigate their mechanisms of action, particularly their impact on Tau interactions with microtubules and their potential to overcome TMZ resistance. My project contributes to a broader collaborative effort aiming to advance new therapeutic strategies for GBM treatment, ultimately aiming to improve patient outcomes.